SAN DIEGO–(BUSINESS
WIRE)–KFx announces the upcoming publications of results on its APPIANFx
Femoral Implant for ACL Reconstruction at the upcoming ORS (Orthopedic Research Society 2012 Meeting) meeting February
4th-7th in San Francisco, CA.
“We believe this is a first ever report of a biomechanical
test method that can accurately resolve and directly quantify the individual
displacement components of ACL reconstructions under controlled cyclic and
ultimate loading,” remarked an author, Mark Ehrensberger, Ph.D., Assistant
Professor, Dept of Biomedical Engineering at Dept of Orthopaedic Surgery, State
University of New York at Buffalo.
“This is a forward-thinking study combined with a
comparative outcome versus the current market leader in ACL aperture fixation.
The results encouraged us in our commercialization plans for market
introduction of this exceptional technology platform for the ACL procedure,”
remarked Tate Scott, president and CEO of KFx Medical Corporation.
“Our core technology platform enables us to provide implants
for several distinct clinical procedures. As we anticipated, with the high
adoption rate of our recently released APPIANFx Biceps Implant, customers have
encouraged us to incorporate these significant core attributes into a femoral
implant as well as other orthopedic procedures.”
The new APPIANFx line of implants from KFx reattach tissue
to, and in, bone in shoulder, knee, foot and ankle procedures which combined
exceed well over 1 million annual surgical procedures in the United States.
Product offerings include those that directly place and secure tissue into bone
both with and without the use of sutures.
About KFx Medical Corporation
Headquartered in Carlsbad,
Calif., KFx Medical Corporation
was founded in 2003 to develop products for tissue fixation in a variety of
orthopedic surgical procedures performed on the shoulder, knee, foot, and
ankle. KFx provides simple systems for orthopedic surgeons focused on sports
medicine. The company is privately held – Investors include Alloy Ventures, Charter Life Sciences, Arboretum Ventures, Montreux Equity Partners, and MB Venture Partners.
Posted by Sean Fenske, Editor-in-Chief, MDT
